Fate Therapeutics Inc (FATE) 5.00 $FATE
Fate Therapeutics to Present at the 2015 Leerink Global Healthcare Conference
GlobeNewswire - Thu Feb 05, 3:09PM CST
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced that Christian Weyer, M.D., M.A.S., President and Chief Executive Officer, will present at the 2015 Leerink Global Healthcare Conference on Thursday, February 12, 2015 at 1:50 pm EST in New York, NY.
FATE: 5.00 (-0.07)
Muscular Dystrophy Therapeutic Pipeline Review Research H2 2014 Report Available at RnRMarketResearch.com
PRWeb - Mon Jan 19, 4:31PM CST
The report " Muscular Dystrophy Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Muscular Dystrophy. Muscular dystrophy is a group of diseases that cause progressive weakness and loss of muscle mass. In muscular dystrophy, abnormal genes interfere with the production of proteins needed to form healthy muscle. All muscular dystrophies are inherited. Each type of muscular dystrophy is associated with a distinct genetic mutation. The nature of the gene mutation and which chromosome it is located on determine the characteristics of the muscular dystrophy and the way the disease is passed from one generation to the next. The symptoms and age of onset depend on the type of muscular dystrophy. Symptoms of muscular dystrophy often include problems with coordination and mobility with frequent falls, muscle weakness & joint stiffness. Complete Report is Available at http://www.rnrmarketresearch.com/muscular-dys...eport.html .
FATE: 5.00 (-0.07), ISIS: 63.86 (-0.43), SRPT: 12.76 (+0.11)
Fate Therapeutics Announces Key 2015 Objectives for the Advancement of Programmed Cellular Therapeutics Pipeline
GlobeNewswire - Mon Jan 12, 6:07AM CST
Primary Endpoint Read-outs from Adult PUMA and Pediatric PROMPT Studies of PROHEMA in Hematologic Malignancies Expected in mid-2015
FATE: 5.00 (-0.07)
Fate Therapeutics to Present at Biotech Showcase 2015
GlobeNewswire - Tue Jan 06, 6:01AM CST
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced that Christian Weyer, M.D., M.A.S., President and Chief Executive Officer, will present an overview of the Company's programs at the 7 Annual Biotech Showcase conference on Monday, January 12, 2015 at 11:30 am PST in San Francisco, CA.
FATE: 5.00 (-0.07)
Will Fate Therapeutics (FATE) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 05, 6:23AM CST
Will Fate Therapeutics (FATE) Continue to Surge Higher?
FATE: 5.00 (-0.07)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 12:05PM CST
FATE: 5.00 (-0.07), SIBC: 21.10 (+0.22), FUR: 16.07 (-0.11), DRAM: 2.39 (-0.04), NRX: 6.67 (-0.14), MEIL: 1.64 (-0.01), MIG: 8.35 (unch), BCLI: 3.86 (-0.02), ABAC: 1.59 (unch), GBR: 1.48 (-0.10), NDRM: 10.76 (+0.22), RCMT: 5.85 (+0.11), AGRX: 8.57 (-0.41), REN: 1.14 (unch), KEG: 2.14 (+0.08), LIME: 2.69 (+0.14), CALA: 16.11 (+0.62), CJJD: 2.59 (-0.01), CBMG: 24.32 (-1.17), GNI: 10.94 (+0.15)
Equities Reward Long-Term Investors: Analyst Notes on Weatherford, ExxonMobil, Ally, UBIC Inc. and Fate Therapeutics
PR Newswire - Mon Dec 22, 8:20AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Weatherford (NYSE: WFT), ExxonMobil (NYSE: XOM), Ally (NYSE: ALLY), UBIC Inc. (NASDAQ: UBIC), and Fate Therapeutics (NASDAQ: FATE). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
FATE: 5.00 (-0.07), UBIC: 20.89 (+1.40), ALLY: 22.05 (+0.21), WFT: 12.17 (+0.55), XOM: 93.37 (+1.00)
Fate Therapeutics Announces Interim Data From Ongoing Phase 2 PUMA Study
GlobeNewswire - Thu Dec 18, 6:06AM CST
Key Metrics of Neutrophil Engraftment Improved in PROHEMA Arm
FATE: 5.00 (-0.07)
Lysosomal Storage Disorder - Pipeline Review, H1 2014
M2 - Mon Dec 15, 4:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/9z3fm9/lysosomal_storage) has announced the addition of the "Lysosomal Storage Disorder - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Lysosomal Storage Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lysosomal Storage Disorder and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Lysosomal Storage Disorder - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Lysosomal Storage Disorder pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Sangamo BioSciences, Inc. - Neuralstem, Inc. - Amicus Therapeutics, Inc. - Cytomedix, Inc. - AngioChem Inc. - Zymenex A/S - Synageva BioPharma Corp. - Fate Therapeutics, Inc. - to-BBB technologies BV - REGiMMUNE Corporation - biOasis Technologies Inc. - ArmaGen Technologies, Inc. - Orphazyme ApS - Oxyrane Belgium NV - Ultragenyx Pharmaceutical Inc. - Minoryx Therapeutics s.l. For more information visit http://www.researchandmarkets.com/research/9z...al_storage
FATE: 5.00 (-0.07), GEVA: 99.75 (-1.68), SGMO: 15.40 (+0.14), FOLD: 8.36 (-0.11), CUR: 3.41 (+0.13)
Hearing Disorders - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/skj5jn/hearing_disorders) has announced the addition of the "Hearing Disorders - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hearing Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hearing Disorders and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hearing Disorders - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hearing Disorders pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Affichem - AudioCure Pharma GmbH - Edison Pharmaceuticals, Inc. - Fate Therapeutics, Inc. - Living Cell Technologies Limited - Novartis AG - Otologic Pharmaceutics, Inc. - Pharmicell Co., Ltd. - Quark Pharmaceuticals, Inc. - Sound Pharmaceuticals, Inc. - uniQure NV For more information visit http://www.researchandmarkets.com/research/sk..._disorders
FATE: 5.00 (-0.07), NVS: 102.20 (-0.17)
Fate Therapeutics Highlights Effects of Nutrient-Rich Media on Ex Vivo Programmed CD34+ Cells Sourced From Umbilical Cord Blood
GlobeNewswire - Mon Dec 08, 12:00PM CST
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, will present today an overview of the effects of using its nutrient-rich media (NRM) formulation in the ex vivo programming of CD34+ cells sourced from umbilical cord blood. Scientists from Fate Therapeutics have shown that, using the Company's NRM formulation as compared to a standard cell processing media commonly used in clinical practice, CD34+ cells programmed with FT1050 (16,16 dimethyl prostaglandin E2 , or dmPGE2) had an 8-fold increase in CXCR4 gene expression and significantly increased cell-surface protein expression of CXCR4, a key receptor implicated in the homing of hematopoietic stem cells (HSCs) to the bone marrow niche. Additionally, ex vivo programmed CD34+ cells exhibited a more than two-fold improvement in HSC engraftment in a xeno-transplantation study in NSG mice at 12-weeks post-transplant. These findings will be presented today at the 56 Annual Meeting and Exposition of the American Society of Hematology (ASH) in San Francisco, California during a poster presentation entitled "Ex Vivo Pharmacologic Modulation in a Nutrient-Rich Medium to Accelerate Engraftment of Human Umbilical Cord Blood."
FATE: 5.00 (-0.07)
Fate Therapeutics Unveils Preclinical Findings of Newly-Identified Small Molecule Modulator Combination for Ex Vivo Programming of Mobilized Peripheral Blood
GlobeNewswire - Sat Dec 06, 11:00AM CST
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, released preclinical data today highlighting the pharmacological properties of ex vivo programmed hematopoietic cells sourced from mobilized peripheral blood at the 56 Annual Meeting and Exposition of the American Society of Hematology (ASH). Using a newly-identified combination of two small molecule modulators, scientists from Fate Therapeutics demonstrated that both T-cells and CD34+ cells from mobilized peripheral blood can be modulated ex vivo, with preclinical evidence pointing to the programmed hematopoietic cells having improved therapeutic potential.
FATE: 5.00 (-0.07)
Cellular Research Launches Precise(TM) Targeted RNASeq Assays
PR Newswire - Fri Dec 05, 7:00AM CST
Cellular Research today announced the commercial launch of its Precise(TM) targeted RNASeq assays. The company also announced the commercial availability of application-focused panels for the Precise assays, including panels designed for oncology, induced pluripotent stem cells and immunology. The company highlighted an early access program for a single cell version of the Precise product, which allows customers to start with single cells and obtain direct molecular counts of RNA transcripts.
FATE: 5.00 (-0.07)
Fate Therapeutics to Present at Piper Jaffray 26th Annual Healthcare Conference
GlobeNewswire - Tue Nov 25, 3:11PM CST
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that Christian Weyer, M.D., M.A.S., President and Chief Executive Officer, will present an overview of the company's programs at the Piper Jaffray 26 Annual Healthcare Conference on Tuesday, December 2, 2014 at 12:10 pm EST in New York, NY.
FATE: 5.00 (-0.07)
Warren Buffett Pick CBI Tumbles On Rating Downgrade
at The Street - Mon Nov 24, 12:00PM CST
Amicus Therapeutics, Inc. (NASDAQ:FOLD), Coronado Biosciences Inc (NASDAQ:CNDO) and Receptos Inc (NASDAQ:RCPT) hit midday posting major gains this Monday. Getting a sluggish start to the week are Fa...
CBI: 38.69 (+0.83), FATE: 5.00 (-0.07), CNDO: 2.28 (+0.03), RCPT: 115.83 (-0.66), FOLD: 8.36 (-0.11)
Fate Therapeutics (FATE) Catches Eye: Stock Adds 6.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 19, 8:11AM CST
Fate Therapeutics, Inc. (FATE) was a big mover last session, as the company saw its shares rise over 6% on the day.
AGEN: 5.03 (-0.01), FATE: 5.00 (-0.07), AMAG: 41.49 (+0.23), AFFX: 11.45 (+0.02)
PharmaSphere: Emerging Biotechnologies - Stem Cell Therapy
M2 - Tue Nov 18, 9:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/f3mqsf/pharmasphere) has announced the addition of the "PharmaSphere: Emerging Biotechnologies - Stem Cell Therapy" report to their offering. "PharmaSphere: Emerging Biotechnologies - Stem Cell Therapy", provides strategic analysis of the global stem cells industry. It discusses key development trends, regulatory requirements in various markets, recent deals activity and industry dynamic trends, as well as describes the operations strategy of these companies. Analyze and track the strategies that companies are using to enter and/or strengthen their position in the evolving stem cell industry, as well as efforts being made by innovator companies like Pfizer and Novartis to enter this market. Furthermore, it includes a geographical segmentation of various markets including the EU and US, as well as emerging markets such as China, India, SouthKorea, and Israel-providing in-depth analysis of these markets' regulatory framework, key domestic players and their stem cell pipelines, and strategic outlook. Throughout the report, Our analysts provide you with expert insight, expanding on each strategy and factor discussed, with the aim of providing you with the tools needed for making informed business decisions. Key Questions Answered - What are the key market drivers of the global stem cell industry? - Who are the top players involved in the development of stem cell therapies in developed as well as developing countries? - What are the main regulatory measures affecting the stem cell industry in the US, Europe, Japan, India, South Korea, China and Israel? - What are the major trends in stem cell clinical trials and profiles of key investigators? - What specific strategies are companies utilizing to combat some of the challenges currently facing the development of therapies in the global stem cell industry? Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Stem Cell Overview 4 Stem Cell Pipeline 5 Stem Cell Clinical Trials 6 Stem Cell Deals 7 Stem Cell Regulation 8 Company Landscape 9 Strategic Outlook 10 Appendix Companies Mentioned - Advanced Cell Technology - Anterogen - Asterias Biotherapeutics - Athersys - Bioheart - Bone Therapeutics - BrainStorm Cell Therapeutics - CHA Bio & Diostech - California Stem Cell - Capricor Therapeutics - Cardio3 BioSciences - Celgene - Cell Cure Neurosciences - Cellerant Therapeutics - Cellular Biomedicine Group - Cytomedix - Escape Therapeutics - Fate Therapeutics - Gamida Cell - Histocell - Orbsen Therapeutics - Pharmicell - Pluristem - Promethera Biosciences - ReNeuron - Reliance Life Sciences - Shenzhen Beike Biotechnology - StemCells - Stemedica - Stempeutics For more information visit http://www.researchandmarkets.com/research/f3...armasphere
FATE: 5.00 (-0.07), AST: 3.85 (+0.13), CBMG: 24.32 (-1.17), BCLI: 3.86 (-0.02), NVS: 102.20 (-0.17), CELGZ: 3.17 (-0.04)
Fate Therapeutics' (FATE) CEO Dr. Christian Weyer on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 11, 7:28PM CST
FATE: 5.00 (-0.07)
Fate Therapeutics to Present at the 2015 Leerink Global Healthcare Conference
GlobeNewswire - Thu Feb 05, 3:09PM CST
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced that Christian Weyer, M.D., M.A.S., President and Chief Executive Officer, will present at the 2015 Leerink Global Healthcare Conference on Thursday, February 12, 2015 at 1:50 pm EST in New York, NY.
FATE: 5.00 (-0.07)
Muscular Dystrophy Therapeutic Pipeline Review Research H2 2014 Report Available at RnRMarketResearch.com
PRWeb - Mon Jan 19, 4:31PM CST
The report " Muscular Dystrophy Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Muscular Dystrophy. Muscular dystrophy is a group of diseases that cause progressive weakness and loss of muscle mass. In muscular dystrophy, abnormal genes interfere with the production of proteins needed to form healthy muscle. All muscular dystrophies are inherited. Each type of muscular dystrophy is associated with a distinct genetic mutation. The nature of the gene mutation and which chromosome it is located on determine the characteristics of the muscular dystrophy and the way the disease is passed from one generation to the next. The symptoms and age of onset depend on the type of muscular dystrophy. Symptoms of muscular dystrophy often include problems with coordination and mobility with frequent falls, muscle weakness & joint stiffness. Complete Report is Available at http://www.rnrmarketresearch.com/muscular-dys...eport.html .
FATE: 5.00 (-0.07), ISIS: 63.86 (-0.43), SRPT: 12.76 (+0.11)
Fate Therapeutics Announces Key 2015 Objectives for the Advancement of Programmed Cellular Therapeutics Pipeline
GlobeNewswire - Mon Jan 12, 6:07AM CST
Primary Endpoint Read-outs from Adult PUMA and Pediatric PROMPT Studies of PROHEMA in Hematologic Malignancies Expected in mid-2015
FATE: 5.00 (-0.07)
Fate Therapeutics to Present at Biotech Showcase 2015
GlobeNewswire - Tue Jan 06, 6:01AM CST
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced that Christian Weyer, M.D., M.A.S., President and Chief Executive Officer, will present an overview of the Company's programs at the 7 Annual Biotech Showcase conference on Monday, January 12, 2015 at 11:30 am PST in San Francisco, CA.
FATE: 5.00 (-0.07)
Will Fate Therapeutics (FATE) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 05, 6:23AM CST
Will Fate Therapeutics (FATE) Continue to Surge Higher?
FATE: 5.00 (-0.07)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 12:05PM CST
FATE: 5.00 (-0.07), SIBC: 21.10 (+0.22), FUR: 16.07 (-0.11), DRAM: 2.39 (-0.04), NRX: 6.67 (-0.14), MEIL: 1.64 (-0.01), MIG: 8.35 (unch), BCLI: 3.86 (-0.02), ABAC: 1.59 (unch), GBR: 1.48 (-0.10), NDRM: 10.76 (+0.22), RCMT: 5.85 (+0.11), AGRX: 8.57 (-0.41), REN: 1.14 (unch), KEG: 2.14 (+0.08), LIME: 2.69 (+0.14), CALA: 16.11 (+0.62), CJJD: 2.59 (-0.01), CBMG: 24.32 (-1.17), GNI: 10.94 (+0.15)
Equities Reward Long-Term Investors: Analyst Notes on Weatherford, ExxonMobil, Ally, UBIC Inc. and Fate Therapeutics
PR Newswire - Mon Dec 22, 8:20AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Weatherford (NYSE: WFT), ExxonMobil (NYSE: XOM), Ally (NYSE: ALLY), UBIC Inc. (NASDAQ: UBIC), and Fate Therapeutics (NASDAQ: FATE). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
FATE: 5.00 (-0.07), UBIC: 20.89 (+1.40), ALLY: 22.05 (+0.21), WFT: 12.17 (+0.55), XOM: 93.37 (+1.00)
Fate Therapeutics Announces Interim Data From Ongoing Phase 2 PUMA Study
GlobeNewswire - Thu Dec 18, 6:06AM CST
Key Metrics of Neutrophil Engraftment Improved in PROHEMA Arm
FATE: 5.00 (-0.07)
Lysosomal Storage Disorder - Pipeline Review, H1 2014
M2 - Mon Dec 15, 4:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/9z3fm9/lysosomal_storage) has announced the addition of the "Lysosomal Storage Disorder - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Lysosomal Storage Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lysosomal Storage Disorder and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Lysosomal Storage Disorder - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Lysosomal Storage Disorder pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Sangamo BioSciences, Inc. - Neuralstem, Inc. - Amicus Therapeutics, Inc. - Cytomedix, Inc. - AngioChem Inc. - Zymenex A/S - Synageva BioPharma Corp. - Fate Therapeutics, Inc. - to-BBB technologies BV - REGiMMUNE Corporation - biOasis Technologies Inc. - ArmaGen Technologies, Inc. - Orphazyme ApS - Oxyrane Belgium NV - Ultragenyx Pharmaceutical Inc. - Minoryx Therapeutics s.l. For more information visit http://www.researchandmarkets.com/research/9z...al_storage
FATE: 5.00 (-0.07), GEVA: 99.75 (-1.68), SGMO: 15.40 (+0.14), FOLD: 8.36 (-0.11), CUR: 3.41 (+0.13)
Hearing Disorders - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/skj5jn/hearing_disorders) has announced the addition of the "Hearing Disorders - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hearing Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hearing Disorders and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hearing Disorders - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hearing Disorders pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Affichem - AudioCure Pharma GmbH - Edison Pharmaceuticals, Inc. - Fate Therapeutics, Inc. - Living Cell Technologies Limited - Novartis AG - Otologic Pharmaceutics, Inc. - Pharmicell Co., Ltd. - Quark Pharmaceuticals, Inc. - Sound Pharmaceuticals, Inc. - uniQure NV For more information visit http://www.researchandmarkets.com/research/sk..._disorders
FATE: 5.00 (-0.07), NVS: 102.20 (-0.17)
Fate Therapeutics Highlights Effects of Nutrient-Rich Media on Ex Vivo Programmed CD34+ Cells Sourced From Umbilical Cord Blood
GlobeNewswire - Mon Dec 08, 12:00PM CST
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, will present today an overview of the effects of using its nutrient-rich media (NRM) formulation in the ex vivo programming of CD34+ cells sourced from umbilical cord blood. Scientists from Fate Therapeutics have shown that, using the Company's NRM formulation as compared to a standard cell processing media commonly used in clinical practice, CD34+ cells programmed with FT1050 (16,16 dimethyl prostaglandin E2 , or dmPGE2) had an 8-fold increase in CXCR4 gene expression and significantly increased cell-surface protein expression of CXCR4, a key receptor implicated in the homing of hematopoietic stem cells (HSCs) to the bone marrow niche. Additionally, ex vivo programmed CD34+ cells exhibited a more than two-fold improvement in HSC engraftment in a xeno-transplantation study in NSG mice at 12-weeks post-transplant. These findings will be presented today at the 56 Annual Meeting and Exposition of the American Society of Hematology (ASH) in San Francisco, California during a poster presentation entitled "Ex Vivo Pharmacologic Modulation in a Nutrient-Rich Medium to Accelerate Engraftment of Human Umbilical Cord Blood."
FATE: 5.00 (-0.07)
Fate Therapeutics Unveils Preclinical Findings of Newly-Identified Small Molecule Modulator Combination for Ex Vivo Programming of Mobilized Peripheral Blood
GlobeNewswire - Sat Dec 06, 11:00AM CST
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, released preclinical data today highlighting the pharmacological properties of ex vivo programmed hematopoietic cells sourced from mobilized peripheral blood at the 56 Annual Meeting and Exposition of the American Society of Hematology (ASH). Using a newly-identified combination of two small molecule modulators, scientists from Fate Therapeutics demonstrated that both T-cells and CD34+ cells from mobilized peripheral blood can be modulated ex vivo, with preclinical evidence pointing to the programmed hematopoietic cells having improved therapeutic potential.
FATE: 5.00 (-0.07)
Cellular Research Launches Precise(TM) Targeted RNASeq Assays
PR Newswire - Fri Dec 05, 7:00AM CST
Cellular Research today announced the commercial launch of its Precise(TM) targeted RNASeq assays. The company also announced the commercial availability of application-focused panels for the Precise assays, including panels designed for oncology, induced pluripotent stem cells and immunology. The company highlighted an early access program for a single cell version of the Precise product, which allows customers to start with single cells and obtain direct molecular counts of RNA transcripts.
FATE: 5.00 (-0.07)
Fate Therapeutics to Present at Piper Jaffray 26th Annual Healthcare Conference
GlobeNewswire - Tue Nov 25, 3:11PM CST
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that Christian Weyer, M.D., M.A.S., President and Chief Executive Officer, will present an overview of the company's programs at the Piper Jaffray 26 Annual Healthcare Conference on Tuesday, December 2, 2014 at 12:10 pm EST in New York, NY.
FATE: 5.00 (-0.07)
Warren Buffett Pick CBI Tumbles On Rating Downgrade
at The Street - Mon Nov 24, 12:00PM CST
Amicus Therapeutics, Inc. (NASDAQ:FOLD), Coronado Biosciences Inc (NASDAQ:CNDO) and Receptos Inc (NASDAQ:RCPT) hit midday posting major gains this Monday. Getting a sluggish start to the week are Fa...
CBI: 38.69 (+0.83), FATE: 5.00 (-0.07), CNDO: 2.28 (+0.03), RCPT: 115.83 (-0.66), FOLD: 8.36 (-0.11)
Fate Therapeutics (FATE) Catches Eye: Stock Adds 6.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 19, 8:11AM CST
Fate Therapeutics, Inc. (FATE) was a big mover last session, as the company saw its shares rise over 6% on the day.
AGEN: 5.03 (-0.01), FATE: 5.00 (-0.07), AMAG: 41.49 (+0.23), AFFX: 11.45 (+0.02)
PharmaSphere: Emerging Biotechnologies - Stem Cell Therapy
M2 - Tue Nov 18, 9:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/f3mqsf/pharmasphere) has announced the addition of the "PharmaSphere: Emerging Biotechnologies - Stem Cell Therapy" report to their offering. "PharmaSphere: Emerging Biotechnologies - Stem Cell Therapy", provides strategic analysis of the global stem cells industry. It discusses key development trends, regulatory requirements in various markets, recent deals activity and industry dynamic trends, as well as describes the operations strategy of these companies. Analyze and track the strategies that companies are using to enter and/or strengthen their position in the evolving stem cell industry, as well as efforts being made by innovator companies like Pfizer and Novartis to enter this market. Furthermore, it includes a geographical segmentation of various markets including the EU and US, as well as emerging markets such as China, India, SouthKorea, and Israel-providing in-depth analysis of these markets' regulatory framework, key domestic players and their stem cell pipelines, and strategic outlook. Throughout the report, Our analysts provide you with expert insight, expanding on each strategy and factor discussed, with the aim of providing you with the tools needed for making informed business decisions. Key Questions Answered - What are the key market drivers of the global stem cell industry? - Who are the top players involved in the development of stem cell therapies in developed as well as developing countries? - What are the main regulatory measures affecting the stem cell industry in the US, Europe, Japan, India, South Korea, China and Israel? - What are the major trends in stem cell clinical trials and profiles of key investigators? - What specific strategies are companies utilizing to combat some of the challenges currently facing the development of therapies in the global stem cell industry? Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Stem Cell Overview 4 Stem Cell Pipeline 5 Stem Cell Clinical Trials 6 Stem Cell Deals 7 Stem Cell Regulation 8 Company Landscape 9 Strategic Outlook 10 Appendix Companies Mentioned - Advanced Cell Technology - Anterogen - Asterias Biotherapeutics - Athersys - Bioheart - Bone Therapeutics - BrainStorm Cell Therapeutics - CHA Bio & Diostech - California Stem Cell - Capricor Therapeutics - Cardio3 BioSciences - Celgene - Cell Cure Neurosciences - Cellerant Therapeutics - Cellular Biomedicine Group - Cytomedix - Escape Therapeutics - Fate Therapeutics - Gamida Cell - Histocell - Orbsen Therapeutics - Pharmicell - Pluristem - Promethera Biosciences - ReNeuron - Reliance Life Sciences - Shenzhen Beike Biotechnology - StemCells - Stemedica - Stempeutics For more information visit http://www.researchandmarkets.com/research/f3...armasphere
FATE: 5.00 (-0.07), AST: 3.85 (+0.13), CBMG: 24.32 (-1.17), BCLI: 3.86 (-0.02), NVS: 102.20 (-0.17), CELGZ: 3.17 (-0.04)
Fate Therapeutics' (FATE) CEO Dr. Christian Weyer on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 11, 7:28PM CST
FATE: 5.00 (-0.07)
